NEWM&A

Eli Lilly (LLY) acquires Centessa for up to $7.8 billion

Published on 3/31/2026

#LLY#Centessa#M&A#pharmaceuticals
Eli Lilly (LLY) acquires Centessa for up to $7.8 billion

AI Summary

Eli Lilly (LLY) announced its acquisition of Centessa Pharmaceuticals in a deal valued up to $7.8 billion, aiming to diversify into sleep disorder treatments. Centessa's lead therapy targets excessive daytime sleepiness and is currently in mid-stage studies. Lilly's offer includes $38 per share in cash, a 37.8% premium, and a contingent value right worth about $1.5 billion. Centessa's shares rose 46% in premarket trading following the announcement, which is set to close in the third quarter.

Source: Read original article (opens in new tab)

Related News

Berkshire Hathaway (BRK.A) Charity Lunch Auction Returns with $19M Record
M&A

Berkshire Hathaway (BRK.A) Charity Lunch Auction Returns with $19M Record

Mar 31

McCormick (MKC) stock rises amid Unilever merger discussions
M&A

McCormick (MKC) stock rises amid Unilever merger discussions

Mar 31

Schroders (SDR) Appoints Patrick Schwyzer as Head of Client Group
M&A

Schroders (SDR) Appoints Patrick Schwyzer as Head of Client Group

Mar 31

AGA Precision Systems (AGA) Signs Supply Deal with Turbo-Jet Products
M&A

AGA Precision Systems (AGA) Signs Supply Deal with Turbo-Jet Products

Mar 31